Report in English with a Dutch summary (KCE reports 63A)
Report in English with a Dutch summary (KCE reports 63A)
Report in English with a Dutch summary (KCE reports 63A)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
44 Breast Cancer <strong>KCE</strong> <strong>reports</strong> 63<br />
178. Rutqvist, L.E., C. Rose, and E. Cavall<strong>in</strong>-Stahl, A systematic overview of radiation therapy<br />
effects <strong>in</strong> breast cancer. Acta Oncologica, 2003. 42(5-6): p. 532-45.<br />
179. Malmstrom, P., et al., Breast conservation surgery, <strong>with</strong> and <strong>with</strong>out radiotherapy, <strong>in</strong> women<br />
<strong>with</strong> lymph node-negative breast cancer: a randomised cl<strong>in</strong>ical trial <strong>in</strong> a population <strong>with</strong> access to<br />
public mammography screen<strong>in</strong>g. European Journal of Cancer, 2003. 39(12): p. 1690-7.<br />
180. Rouesse, J., et al., A phase III randomized trial compar<strong>in</strong>g adjuvant concomitant<br />
chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy <strong>in</strong> operable<br />
node-positive breast cancer: f<strong>in</strong>al results. International Journal of Radiation Oncology, Biology,<br />
Physics, 2006. 64(4): p. 1072-80.<br />
181. Cunc<strong>in</strong>s-Hearn, A., et al., A systematic review of <strong>in</strong>traoperative radiotherapy <strong>in</strong> early breast<br />
cancer. Breast Cancer Res Treat, 2004. 85(3): p. 271-80.<br />
182. Poole, C.J., et al., Epirubic<strong>in</strong> and cyclophosphamide, methotrexate, and fluorouracil as<br />
adjuvant therapy for early breast cancer.[see comment]. New England Journal of Medic<strong>in</strong>e, 2006.<br />
355(18): p. 1851-62.<br />
183. Land, S.R., et al., Health-related quality of life <strong>in</strong> axillary node-negative, estrogen receptornegative<br />
breast cancer patients undergo<strong>in</strong>g AC versus CMF chemotherapy: f<strong>in</strong>d<strong>in</strong>gs from the<br />
National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Research & Treatment,<br />
2004. 86(2): p. 153-64.<br />
184. Fargeot, P., et al., Disease-free survival advantage of weekly epirubic<strong>in</strong> plus tamoxifen versus<br />
tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6year<br />
follow-up results of the French adjuvant study group 08 trial.[see comment][erratum appears<br />
<strong>in</strong> J Cl<strong>in</strong> Oncol. 2005 Jan 1;23(1):248]. Journal of Cl<strong>in</strong>ical Oncology, 2004. 22(23): p. 4622-30.<br />
185. Bonadonna, G., et al., Cl<strong>in</strong>ical relevance of different sequenc<strong>in</strong>g of doxorubic<strong>in</strong> and<br />
cyclophosphamide, methotrexate, and Fluorouracil <strong>in</strong> operable breast cancer. Journal of Cl<strong>in</strong>ical<br />
Oncology, 2004. 22(9): p. 1614-20.<br />
186. Fumoleau, P., et al., Randomized trial compar<strong>in</strong>g six versus three cycles of epirubic<strong>in</strong>-based<br />
adjuvant chemotherapy <strong>in</strong> premenopausal, node-positive breast cancer patients: 10-year follow-up<br />
results of the French Adjuvant Study Group 01 trial. Journal of Cl<strong>in</strong>ical Oncology, 2003. 21(2): p.<br />
298-305.<br />
187. Mart<strong>in</strong>, M., et al., Doxorubic<strong>in</strong> <strong>in</strong> comb<strong>in</strong>ation <strong>with</strong> fluorouracil and cyclophosphamide (i.v.<br />
FAC regimen, day 1, 21) versus methotrexate <strong>in</strong> comb<strong>in</strong>ation <strong>with</strong> fluorouracil and<br />
cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast<br />
cancer: a study by the GEICAM group. Annals of Oncology, 2003. 14(6): p. 833-42.<br />
188. Sartor, C.I., et al., Effect of addition of adjuvant paclitaxel on radiotherapy delivery and<br />
locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.[see<br />
comment]. Journal of Cl<strong>in</strong>ical Oncology, 2005. 23(1): p. 30-40.<br />
189. Green, M.C., et al., Weekly paclitaxel improves pathologic complete remission <strong>in</strong> operable<br />
breast cancer when compared <strong>with</strong> paclitaxel once every 3 weeks.[see comment]. Journal of<br />
Cl<strong>in</strong>ical Oncology, 2005. 23(25): p. 5983-92.<br />
190. Bra<strong>in</strong>, E.G.C., et al., Life-threaten<strong>in</strong>g sepsis associated <strong>with</strong> adjuvant doxorubic<strong>in</strong> plus<br />
docetaxel for <strong>in</strong>termediate-risk breast cancer.[see comment]. JAMA, 2005. 293(19): p. 2367-71.<br />
191. Bear, H.D., et al., Sequential preoperative or postoperative docetaxel added to preoperative<br />
doxorubic<strong>in</strong> plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast<br />
and Bowel Project Protocol B-27. Journal of Cl<strong>in</strong>ical Oncology, 2006. 24(13): p. 2019-27.<br />
192. Gianni, L., et al., Feasibility and tolerability of sequential doxorubic<strong>in</strong>/paclitaxel followed by<br />
cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as<br />
preoperative therapy. Cl<strong>in</strong>ical Cancer Research, 2005. 11(24 Pt 1): p. 8715-21.<br />
193. Cleator, S.J., et al., Good cl<strong>in</strong>ical response of breast cancers to neoadjuvant chemoendocr<strong>in</strong>e<br />
therapy is associated <strong>with</strong> improved overall survival. Annals of Oncology, 2005. 16(2): p. 267-72.<br />
194. Danforth, D.N., Jr., et al., Preoperative FLAC/granulocyte-colony-stimulat<strong>in</strong>g factor<br />
chemotherapy for stage II breast cancer: a prospective randomized trial.[see comment]. Annals of<br />
Surgical Oncology, 2003. 10(6): p. 635-44.
Change language